| VCP/p97 (Valosin-Containing Protein) | |
|---|---|
| Gene | VCP |
| UniProt | P55072 |
| PDB | 5FTK, 3CF3, 5FTN |
| Mol. Weight | 97 kDa monomer (806 aa); ~580 kDa hexamer |
| Localization | Cytoplasm, ER membrane, nucleus |
| Family | AAA+ ATPase family |
| Chromosome | 9p13.3 |
| Diseases | ALS, FTD, IBMPFD, Alzheimer's |
Vcp P97 (Valosin Containing Protein) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Valosin-Containing Protein (VCP), also known as p97 or Cdc48 in yeast, is an abundant and evolutionarily conserved AAA+ ATPase (ATPase Associated with diverse cellular Activities) that serves as a central hub for protein quality control in eukaryotic cells [1][2]. Encoded by the VCP gene on chromosome 9p13.3, this 97 kDa protein assembles into functional hexameric rings that use the energy of ATP hydrolysis to unfold, extract, and segregate ubiquitinated client proteins from membranes, chromatin, and macromolecular complexes for processing by the [ubiquitin-proteasome system[/entities/ubiquitin-proteasome-system or [autophagy[/entities/autophagy [1][3]. VCP is estimated to process approximately 30% of all proteasome-bound substrates, making it one of the most critical enzymes in cellular proteostasis [2].
Autosomal dominant missense mutations in VCP cause a devastating multisystem degenerative disorder known as VCP-associated multisystem proteinopathy (MSP), which can manifest as inclusion body myopathy with Paget's disease of bone and Frontotemporal Dementia (IBMPFD), [amyotrophic lateral sclerosis (ALS)[/diseases/als, [Alzheimer's disease[/diseases/alzheimers, parkinsonism, and Charcot-Marie-Tooth Disease [1][4].
VCP/p97 has a modular domain architecture, with each of its six identical protomers composed of four functional domains [2][3][5]:
The NTD serves as a docking platform for over 40 known cofactors and adaptors. It undergoes large conformational changes (up/down movements) upon ATP binding and hydrolysis in the D1 domain, which regulates cofactor binding and substrate engagement. The NTD adopts a double-ψ barrel fold and switches between coplanar (ADP-bound) and elevated (ATP-bound) positions relative to the D1 ring [3][5].
The D1 domain is a "weak" ATPase that primarily serves a structural role, maintaining hexamer stability. It forms the upper ring of the barrel-shaped hexamer. ATP binding to D1 is constitutive and critical for hexamer assembly, while its hydrolysis rate is comparatively low [2][3].
The D2 domain is the major catalytic ATPase engine, providing the mechanical force for substrate unfolding and translocation through the central pore of the hexamer. D2 undergoes coordinated conformational changes during the ATPase cycle, with successive subunits firing in a hand-over-hand mechanism to thread substrates through the ~15 Å central channel [3][5].
The unstructured C-terminal region contains post-translational modification sites (phosphorylation, acetylation) that regulate VCP activity and cofactor interactions [2].
Cryo-EM structures at 2.3 Å resolution (PDB: 5FTK) have revealed the detailed conformational landscape of the hexamer in ADP-bound and ATPγS-bound states, showing how nucleotide state controls NTD positioning and pore opening [5].
VCP/p97 is one of the most abundant cytoplasmic proteins, comprising approximately 1% of total cellular protein. Its functions span virtually every major cellular process involving protein turnover [1][2][3]:
VCP extracts misfolded proteins from the endoplasmic reticulum membrane for proteasomal degradation, working with the Ufd1–Npl4 heterodimer as its primary adaptor complex. This is the best-characterized VCP pathway and is essential for ER protein quality control [2][1].
VCP participates in the extraction and degradation of damaged outer mitochondrial membrane proteins and cooperates with [PINK1[/proteins/pink1-protein/[Parkin[/proteins/parkin-mediated mitophagy pathways. VCP is recruited to depolarized mitochondria to facilitate their clearance through [autophagy[/entities/autophagy [1][2].
VCP is required for the maturation of autophagosomes and their fusion with lysosomes. Loss of VCP function leads to accumulation of immature autophagosomes containing ubiquitinated substrates, a hallmark of VCP disease pathology [1][3].
VCP extracts stalled RNA polymerase II and damaged histones from chromatin, facilitating DNA damage repair. It is recruited to double-strand breaks and is essential for homologous recombination and non-homologous end joining [2].
VCP regulates endosome sorting and the degradation of ubiquitinated membrane receptors, linking it to growth factor signaling and synaptic receptor turnover in [neurons[/entities/neurons [1].
Over 50 pathogenic missense mutations have been identified in VCP, mostly clustered at the interface between the NTD and D1 domains [1][4]. The most common mutation is R155H, accounting for approximately 50% of all VCP disease cases. These mutations cause a spectrum of phenotypes [4][3]:
VCP mutations cause disease through gain-of-function mechanisms that hyperactivate ATPase activity [1][4][3]:
Beyond inherited MSP, VCP dysfunction has been implicated in sporadic [Alzheimer's disease[/diseases/alzheimers, where it may contribute to impaired clearance of [Amyloid-Beta[/proteins/Amyloid-Beta and tau[/proteins/tau-protein aggregates [1].
VCP/p97 is an active drug target, with inhibitors explored for both cancer and neurodegenerative indications [1][5]:
The study of Vcp P97 (Valosin Containing Protein) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
| Approach | Status | Description |
|---|---|---|
| VCP inhibitors | Preclinical | ML240, NMS-873 for cancer |
| Gene therapy | Research | AAV-VCP for IBMPFD |
| Small molecules | Research | Modulate ATPase activity |
| Protein replacement | Research | Recombinant VCP delivery |